The Phase I trial will study target dose levels of 5 mg/kg, 10 mg/kg and 20 mg/kg of PGN-EDODM1, with safety, transcript splicing and clinical outcome measures data from the 5 mg/kg cohort expected in 2024
established a synergistic therapeutic strategy based on a thermosensitive in situ hydrogel consisting of poloxamer and hyaluronic acid, which allows the co-delivery of Fer-1 and antifungal agents
By charting the types of interventions studied, outcomes assessed, and the main areas of research concentration and scarcity, this review provides a descriptive overview of the field and informs future research directions, thereby supporting clinicians, researchers, and policymakers in developing more evidence-informed approaches to improving care and quality of life for individuals undergoing long-term hemodialysis
Check your manufacturer's instructions
Short-term drug termination was lower among drug recipients predicted by the model to demonstrate the largest HbA1c improvement, owing mostly to variations in SGLT2 inhibitor treatment termination across anticipated differences in glycemic responses
